Merck & Co

Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics

MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.

Merck & Co. Breaks Ground on $1 Billion Biologics Center in US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.

MSD Licenses Cardiovascular Drug from Hengrui Pharma

MSD (Merck & Co.) and Hengrui Pharma recently announced that they have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor.

Merck & Co. Acquires Vaccine Site in Ireland from WuXi

As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.

Merck & Co. Licenses Obesity Drug from Hansoh Pharma

US Merck & Co., operating as MSD outside the US and Canada, and Chinese biopharmaceutical company Hansoh Pharma have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. GLP-1 receptor agonists are primarily used for the treatment of type 2 diabetes and obesity.

Merck & Co. Licenses Investigational Cancer Drug from LaNova

US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from Chinese biotechnology company LaNova Medicines.

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

MSD Animal Health to Acquire Elanco’s Aqua Business

MSD Animal Health, a division of Merck & Co., announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for €1.2 billion ($1.3 billion) in cash. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions.

Merck & Co. to Acquire Caraway Therapeutics

Merck & Co. (MSD) and Caraway Therapeutics announced that the companies have agreed Merck & Co., through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to €557 million ($610 million), including an undisclosed upfront payment and contingent milestone payments.

US Drugmaker Merck & Co. to Add Jobs in Ireland

US drugmaker Merck & Co. plans to add 100 new jobs as part of an expansion project at its site in Carlow, Ireland, which opened in 2008 as the company’s first vaccines facility outside of the US and currently employs 530 people.

Merck Reports Higher-Than-Expected Earnings

Merck & Co to Buy Back Up To $5 Billion Of Its Shares

Merck To Acquire Inspire Pharma For $430 Million

Merck & Co, Parexel Strike Alliance to Develop Biotech Medicines